Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age

Herpes Zoster Clinical Trial

Official title:

A Multi-center, Randomized, Double-blinded, Phase 3 Trial to Evaluate the Efficacy Against Herpes Zoster of a Live Attenuated Varicella-Zoster Virus Vaccine in Adults Over 40 Years of Age

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03314103
• Other study ID #: CS-HZ-2017
• Status: Completed
• Phase: Phase 3
• Start date: October 6, 2017
• Est. completion date: January 19, 2019

Study information

• Verified date: March 2021
• Source: Jiangsu Province Centers for Disease Control and Prevention
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Varicella-zoster virus (VZV) is a herpesvirus that causes two distinct clinical syndromes.Primary infection is manifested as varicella (chickenpox), whereas reactivation of latent VZV results in a localized eruption known as herpes zoster. More than 99.6% of people 40 years of age orolder had evidence of previous VZV infection. This study plans to have 30000 adults 40 years of age or older involoved in a randomized, double-blind, placebo-controlled trial of an investigational live attenuated varicella-zoster virus vaccine. The investigational vaccines are produced by Changchun Changsheng biotechnology co. LTD. The incidence of herpes zoster and the severity, and duration of the associated pain and discomfort were measured after the vaccination. And the safety of the varicella-zoster virus vaccine is also evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30000
• Est. completion date: January 19, 2019
• Est. primary completion date: January 19, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Healthy volunteers aged over 40 years (male or female).
• Able to comply with all clinical trial protocol requirements and willing to complete all the visit plan process during the whole clinical trial observation period.
• Able to understand the content of informed consent and willing to sign the informed consent.
• Able to complete the diary card independently.
• For females only (40-49 years), a negative urine pregnancy test and willing to practice continuous effective contraception during the study.
• Axillary temperature =37.0°C.

Exclusion Criteria:

• Prior history of herpes zoster.
• Prior history of vaccination with herpes zoster vaccine or chickenpox vaccine.
• History of allergic disease likely to be exacerbated by any component of the vaccine.
• Taking immunoglobulins and/or any blood products within the last 3 months or will receive these products during the study period.
• Taking certain pharmaceuticals to be like salicylate kind, including aspirin, and difluorosalicylic, or going to take these medicine during the study period.
• Participation in another research study involving receipt of an investigational product in the last 30 days.
• Prior administration of attenuated vaccine in last 28 days.
• Prior administration of subunit vaccine, inactivated vaccine or allergic therapy in last 14 days.
• History of serious disease and the participation in the clinical trial is likely to increase the disease risk and interfere with the observation of clinical trial index.
• Taking immunosuppressive therapy in last 6 months.
• Any autoimmune disease or immunodeficient state, autoimmune disease or immunodeficient disease.
• Active tuberculosis patient.
• Acute or chronic infections at the vaccination day (axillary temperature>37.0°C).
• Coagulation disorders (coagulation factor deficiency, coagulopathy or platelet disorder) diagnosed by doctors, or obvious bruises or blood coagulation noticed.
• Woman who is breast-feeding.
• Any other conditions may compromise the safety or availability of participants in the judgment of the investigator.

Related Conditions & MeSH terms

• Herpes Zoster

Intervention

Biological:
• One shot of the varicella-zoster virus vaccine
One shot of the live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
• one shot of placebo
one shot of placebo with no live virus

Locations

Country	Name	City	State
China	Zhejiang Provincial Center for Disease Control and Prevention	Hanzhou	Zhejiang
China	Hunan Provincial Center for Disease Control and Prevention	Loudi	Hunan
China	Jiangsu Province Centers for Disease Control and Prevention	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Province Centers for Disease Control and Prevention

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The incidence of herpes zoster 30 days after vaccination.	The incidence of herpes zoster diagnosed in participants 30 days after vaccination.	30 days-2 years after the vaccination
Secondary	The incidence of herpes zoster after vaccination.	The incidence of herpes zoster diagnosed in participants after vaccination.	within 0 day -2 years after the vaccination
Secondary	The incidence of laboratory-confirmed herpes zoster 30 days after vaccination.	The incidence of laboratory-confirmed herpes zoster diagnosed in participants 30 days after vaccination.	30 days-2 years after the vaccination
Secondary	The incidence of herpes zoster with severe postherpetic neuralgia (ZBPI scores=3) 30 days after vaccination.	The incidence of herpes zoster with severe postherpetic neuralgia (ZBPI scores=3) in participants 30 days after vaccination.	30 days-2 years after the vaccination
Secondary	The incidence of herpes zoster with postherpetic neuralgia 30 days after vaccination.	The incidence of herpes zoster with postherpetic neuralgia in participants 30 days after vaccination.	30 days-2 years after the vaccination
Secondary	The incidence of herpes zoster with severe pain (ZBPI scores=3) 30 days after vaccination. Time Frame: 30 days-2 years after the vaccination	30 days-2 years after the vaccination	The incidence of herpes zoster with severe pain (ZBPI scores=3) in participants 30 days after vaccination.
Secondary	Geometric mean titre, geometric mean fold increase and four-fold increase rate of serum for antibody responses 30 days post-vaccination.	Geometric mean titre, geometric mean fold increase and four-fold increase rate of Serum for antibody responses at day 30 post-vaccination	30 days after the vaccination
Secondary	Geometric mean titre, geometric mean fold increase of serum for antibody responses 6 months post-vaccination.	geometric mean titre, geometric mean fold increase of Serum for antibody responses at 6 months post-vaccination	6 months after the vaccination
Secondary	Geometric mean titre, geometric mean fold increase of serum for antibody responses 12 months post-vaccination.	geometric mean titre, geometric mean fold increase of Serum for antibody responses at 12 months post-vaccination	12 months after the vaccination
Secondary	Geometric mean titre, geometric mean fold increase of serum for antibody responses 24 months post-vaccination.	geometric mean titre, geometric mean fold increase of Serum for antibody responses at 24 months post-vaccination	24 months after the vaccination
Secondary	Occurrence of solicited adverse reactions after the vaccination.	Occurrence of solicited adverse reactions within 14 days after the vaccination.	within 14 days after the vaccination
Secondary	Occurrence of adverse reactions after the vaccination.	Occurrence of adverse reactions within 30 days after the vaccination.	within 30 days after the vaccination
Secondary	Occurrence of severe adverse reactions after the vaccination.	Occurrence of severe adverse reactions within 2 years after the vaccination.	within 2 years